ACTR5

Across TCGA pan-cancer cohorts, ACTR5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTR5 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher ACTR5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACTR5 expression acts as an unfavorable survival marker.

ACC, SCLC, and LIHC are the cancer types where ACTR5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.118	0.624	.038	6	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
LIHC	DFS	Median	All	0.101	0.543	.044	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTR5–ACC (OS)

Open the ACC breakdown →